Fig. 4: Subjective assessments of sleep measured by visual analogue scales in the Subjective Quality of Sleep Questionnaire (SQSQ) following the baseline and three treatment nights. | Neuropsychopharmacology

Fig. 4: Subjective assessments of sleep measured by visual analogue scales in the Subjective Quality of Sleep Questionnaire (SQSQ) following the baseline and three treatment nights.

From: Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomised trial

Fig. 4

White bars indicate baseline, black bars indicate placebo, hatched bars indicate 20 mg and grey bars indicate 50 mg. Significant differences between placebo and JNJ-48816274 treatment are indicated by *p < 0.05 and **p < 0.01.

Back to article page